Kura files $100m offer after menin inhibitor results in AML

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the program is firmly back on track – and the biotech has filed a $100 million offering to help fund its future development.